Japan Housing Finance Agency's ¥184.9 Billion Series 69 Structured Issuance Assigned 'AAA (sf)' Rating Feb 13

  • ID: 2394283
  • February 2013
  • Region: Japan
  • Standard & Poors
1 of 3

OVERVIEW JHF's series 69 fixed-rate residential mortgage-secured pass-through notes are a structured note issuance that JHF originated. A pool of residential mortgage loans ultimately backs the notes. We have assigned our 'AAA (sf)' rating to the notes, based on our view of the transaction's legal structure, credit support, and pool characteristics, among other factors. Due to the structural features of this transaction, the rating on the notes depends to an extent on the credit quality of JHF. TOKYO (Standard & Poor's) Feb. 5, 2013--Standard & Poor's Ratings Services today said that it has assigned its 'AAA (sf)' rating to Japan Housing Finance Agency's (JHF; AA-/Negative/A-1+) ¥184.9 billion series 69 fixed-rate residential mortgage-secured pass-through notes. Standard & Poor's rating reflects its...

Companies mentioned in this report are:
- Japan Housing Finance Agency

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Japan Housing Finance Agency

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.